A PHASE I STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF HIGH DOSES OF CAMOSTAT MESYLATE IN HEALTHY SUBJECTS PROVIDES A RATIONALE TO REPURPOSE THE TMPRSS2 INHIBITOR FOR THE TREATMENT OF COVID-19.

被引：0
|
作者：
Kitagawa, J. [1 ]
Arai, H. [1 ]
Iida, H. [1 ]
Mukai, J. [1 ]
Furukawa, K. [1 ]
Ohtsu, S. [1 ]
Nakade, S. [1 ]
Hikima, T. [2 ]
Haranaka, M. [3 ]
Uemura, N. [4 ]
机构：
[1] Ono Pharmaceut, Osaka, Japan
[2] Kyushu Inst Technol, Fukuoka, Japan
[3] SOUSEIKAI Hakata Clin, Fukuoka, Japan
[4] Oita Univ, Oita, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-052
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [21] A phase 1/2 study to evaluate the pharmacokinetics, safety, tolerability, immunogenicity, and pharmacodynamics of Albuferon™ in treatment experience subjects with chronic hepatitis C
    Balan, V
    Sulkowski, M
    Nelson, D
    Everson, G
    Bambury, T
    Recta, J
    Zhong, J
    Mesghali, H
    Murray, J
    Osborn, B
    Novello, L
    Freimuth, W
    Subramanian, G
    HEPATOLOGY, 2003, 38 (04) : 307A - 307A
  • [22] A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CB03-154 in Healthy Subjects
    Zhu, Minjuan
    Hua, Bo
    Li, Baini
    Guo, Ruoling
    Liu, Gang
    Liu, Xiuxiu
    Wan, Hui
    Yao, Shuran
    Song, Chao
    Dou, Jinhui
    Zhang, Xin
    Lu, Zhihong
    Zhou, Xiaolin
    Chen, Huanming
    Gonen, Ofer
    ANNALS OF NEUROLOGY, 2024, 96 : S179 - S180
  • [23] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Derks, Michael
    Anzures-Cabrera, Judith
    Turnbull, Lynn
    Phelan, Mary
    CLINICAL DRUG INVESTIGATION, 2011, 31 (05) : 325 - 335
  • [24] A PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS (PK) OF SINGLE ASCENDING ORAL DOSES OF THE NS3/4A PROTEASE INHIBITOR ITMN 191 IN HEALTHY SUBJECTS
    Bradford, Williamson Z.
    Rubino, Christopher
    Porter, Steve
    Forrest, Alan
    Blatt, Lawrence M.
    Patat, Alain A.
    HEPATOLOGY, 2008, 48 (04) : 1146A - 1146A
  • [25] A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled GDC-0214, a JAK1 Inhibitor, as Single- and Multiple-Ascending Doses in Healthy Volunteers
    Owen, Ryan
    Galanter, Joshua
    Zhu, Rui
    Cai, Fang
    Tom, Jennifer
    Wynne, Chris
    Durk, Matthew
    Chen, Liuxi
    Kenny, Jane
    She, Gao-hong
    Vadhavkar, Shweta
    Hwang, Olivia
    Chen, Hubert
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB17 - AB17
  • [26] Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate - A Potential Treatment for COVID-19
    Bentur, Ohad
    Hutt, Richard
    Brassil, Donna
    Backman, Per
    Gonda, Igor
    Boushey, Homer
    Cahrous, B.
    Coller, Barry
    MacArthur, Robert
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB237 - AB237
  • [27] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor
    Dennie, Justin
    Vandell, Alexander G.
    Inoue, Satoshi
    Gajee, Roohi
    Pav, Joseph
    Zhang, George
    Zamora, Cynthia
    Masuda, Nobuhisa
    Uchiyama, Minoru
    Yamada, Makiko
    Senaldi, Giorgio
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565
  • [28] A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
    Ermer, James
    Martin, Patrick
    Corcoran, Mary
    Matsuo, Yumiko
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (01) : 16 - 29
  • [29] Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
    Kansagra, Kevinkumar A.
    Parmar, Deven
    Jani, Rajendra H.
    Srinivas, Nuggehally R.
    Lickliter, Jason
    Patel, Harilal V.
    Parikh, Devang P.
    Heading, Heather
    Patel, Hardik B.
    Gupta, Rahul J.
    Shah, Chintan Y.
    Patel, Maulik R.
    Dholakia, Vyom N.
    Sukhadiya, Raghav
    Jain, Mukul R.
    Parmar, Krupi V.
    Barot, Kinjal
    CLINICAL PHARMACOKINETICS, 2018, 57 (01) : 87 - 102
  • [30] Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
    Kevinkumar A. Kansagra
    Deven Parmar
    Rajendra H. Jani
    Nuggehally R. Srinivas
    Jason Lickliter
    Harilal V. Patel
    Devang P. Parikh
    Heather Heading
    Hardik B. Patel
    Rahul J. Gupta
    Chintan Y. Shah
    Maulik R. Patel
    Vyom N. Dholakia
    Raghav Sukhadiya
    Mukul R. Jain
    Krupi V. Parmar
    Kinjal Barot
    Clinical Pharmacokinetics, 2018, 57 : 87 - 102
12345